SUPERIORITY OF ENHERTU; A QUESTION TO BE ANSWERED
Author(s): Athira Jayaraj*
Abstract
Approximately 20% of metastatic breast cancers are characterized by overexpression or amplification of human epidermal growth factor receptor 2 (HER2). Trastuzumab emtansine is the standard treatment for patients with HER2 –positive metastatic breast cancer whose disease progresses after treatment with a combination of anti-HER2 antibodies and a taxane. The recent approval of trastuzumab deruxtecan (Enhertu) based on phase 3, multicenter, open-label, randomized trial which compared the efficacy and safety of trastuzumab deruxtecan (a HER2 antibody-drug conjugate) with trastuzumab emtansine. In the present mini-review, we discuss recent findings of clinical studies concerning the pros and cons of Enhertu.